The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Open accessAbstract
RNA plays a central role in the expression of all genes. Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease. The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs. This review will discuss the chemical modifications and molecular mechanisms that make synthetic nucleic acid drugs possible. Lessons learned from recent clinical trials will be summarized. Ongoing clinical trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Argonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Active perception: sensorimotor circuits as a cortical basis for language
Pulvermüller, F., & Fadiga, L. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2811 · Cited by 1,048
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Self-citationArgonaute proteins: functional insights and emerging roles
Meister, G. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3462 · Cited by 1,030
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754 · cited 1×
“Effects were long-lasting and suggest that GalNAc is a promising clinical option for ASOs (33).”
BackgroundCartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
D'Souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 621
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
FDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605
Self-citationThe RNA-induced Silencing Complex: A Versatile Gene-silencing Machine
Pratt, A. J., & MacRae, I. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r900012200 · Cited by 602
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · cited 1×
“duced into biological systems, (ii) poor uptake through cell membranes, (iii) unfavorable biodistribution and pharmacokinetic properties and (iv) sub-optimal binding affinity for complementary sequences (3,4).”
BackgroundStructure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex
Wang, Y., Juranek, S., Li, H., Sheng, G., Tuschl, T., & Patel, D. J. (2008) · Nature · doi:10.1038/nature07666 · Cited by 577
Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Herbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539 · cited 1×
“In cell culture, blocking telomerase with ASOs complementary to the RNA template leads to decreased cell proliferation over a period of weeks (83).”
BackgroundSelf-citationSplice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
Lennox, K. A., & Behlke, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1206 · Cited by 453
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445 · cited 1×
“A second BNA, 2′,4′constrained ethyl nucleic acid ((S)-cET) (15) is now being widely tested in the clinic (16).”
BackgroundRestoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
Molecular Mechanisms of Antisense Oligonucleotides
Crooke, S. T. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0656 · Cited by 396
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Hypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 387
Iwamoto, N., Butler, D. C. D., Svrzikapa, N., Mohapatra, S., Zlatev, I., Sah, D. W. Y., Meena, Standley, S. M., Lu, G., Apponi, L. H., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3948 · Cited by 377
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Pasi, K. J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T., Bevan, D., Austin, S., Hay, C. R., Hegemann, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616569 · Cited by 367
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Aartsma-Rus, A., & Krieg, A. M. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0657 · Cited by 364
Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 360
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 358
Manoharan, M. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00138-4 · Cited by 348
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339
Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 334
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Safety of antisense oligonucleotide and siRNA-based therapeutics
Chi, X., Gatti, P., & Papoian, T. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.013 · Cited by 280
Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., & Corey, D. R. (2012) · Cell · doi:10.1016/j.cell.2012.08.002 · Cited by 278
Self-citationRader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Pfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P. D., & Aronin, N. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.030 · Cited by 261
Single-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Straarup, E. M., Fisker, N., Hedtjärn, M., Lindholm, M. W., Rosenbohm, C., Aarup, V., Hansen, H. F., Ørum, H., Hansen, J. B. R., & Koch, T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq457 · Cited by 249
Dietrich, G., Bubert, A., Gentschev, I., Sokolovic, Z., Simm, A., Catic, A., Kaufmann, S. H. E., Hess, J., Szalay, A. A., & Goebel, W. (1998) · Nature Biotechnology · doi:10.1038/nbt0298-181 · Cited by 246
Minshull, J., & Hunt, T. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.16.6433 · Cited by 243
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 240
Self-citationOttosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L.-J., van der Veer, E., Raney, A. K., Hodges, M. R., & Patick, A. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04220-14 · Cited by 230
Stein, C. A., & Krieg, A. M. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.67 · Cited by 228
Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 225
Sustained effects of nonallele‐specific Huntingtin silencing
Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi‐Carter, R., Hantraye, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21569 · Cited by 216
Burel, S. A., Hart, C. E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H.-H., Younis, H., Sabripour, M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1210 · Cited by 216
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Zimmermann, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B. R., Hutabarat, R., Nochur, S., Vaishnaw, A., & Gollob, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.019 · Cited by 216
Seth, P. P., Vasquez, G., Allerson, C. A., Berdeja, A., Gaus, H., Kinberger, G. A., Prakash, T. P., Migawa, M. T., Bhat, B., & Swayze, E. E. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo902560f · Cited by 211
Haché, M., Swoboda, K. J., Sethna, N., Farrow-Gillespie, A., Khandji, A., Xia, S., & Bishop, K. M. (2016) · Journal of Child Neurology · doi:10.1177/0883073815627882 · Cited by 208
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Baerlocher, G. M., Oppliger Leibundgut, E., Ottmann, O. G., Spitzer, G., Odenike, O., McDevitt, M. A., Röth, A., Daskalakis, M., Burington, B., Stuart, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503479 · Cited by 200
Aartsma-Rus, A. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0665 · Cited by 196
How does RNase H recognize a DNA.RNA hybrid?
Nakamura, H., Oda, Y., Iwai, S., Inoue, H., Ohtsuka, E., Kanaya, S., Kimura, S., Katsuda, C., Katayanagi, K., & Morikawa, K. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11535 · Cited by 193
Exon skipping therapy for Duchenne muscular dystrophy
Kole, R., & Krieg, A. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.008 · Cited by 192
The experimental use of antisense oligonucleotides: a guide for the perplexed
Stein, C. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13885 · Cited by 183
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
Tanowitz, M., Hettrick, L. A., Revenko, A. S., Kinberger, G. A., Prakash, T. P., & Seth, P. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx960 · Cited by 165
Fomivirsen: Clinical Pharmacology and Potential Drug Interactions
Geary, R. S., Henry, S. P., & Grillone, L. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00002 · Cited by 160
van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., & Reesink, H. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13432 · Cited by 159
Lim, S. R., & Hertel, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107632200 · Cited by 159
Gagnon, K. T., Pendergraff, H. M., Deleavey, G. F., Swayze, E. E., Potier, P., Randolph, J., Roesch, E. B., CHATTOPADHYAYA, J. B., Damha, M. J., Bennett, C. F., et al. (2010) · Biochemistry · doi:10.1021/bi101208k · Cited by 153
Self-citationAckermann, E. J., Guo, S., Benson, M. D., Booten, S. L., Freier, S., Hughes, S. G., Kim, T., Kwoh, T. J., Matson, J. E., Norris, D., et al. (2016) · Amyloid · doi:10.1080/13506129.2016.1191458 · Cited by 153
(2003) · Nature Cell Biology · doi:10.1038/ncb0603-490 · Cited by 153
Skotte, N. H., Southwell, A. L., Østergaard, M. E., Carroll, J. B., Warby, S. C., Doty, C. N., Petoukhov, E., Vaid, K., Kordasiewicz, H. B., Watt, A. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107434 · Cited by 139
Spinal muscular atrophy—recent therapeutic advances for an old challenge
Faravelli, I., Nizzardo, M., Comi, G. P., & Corti, S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.77 · Cited by 138 · cited 1×
“Spinal muscular atrophy (SMA) refers to several different motor neuron diseases and is most commonly associated with mutations in the survival motor neuron 1 (SMN1) gene (106).”
BackgroundDuell, P. B., Santos, R. D., Kirwan, B., Witztum, J. L., Tsimikas, S., & Kastelein, J. J. P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.013 · Cited by 134
Yasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J. D., New, M. I., Liebow, A., Fitzgerald, K. J., Querbes, W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406228111 · Cited by 133
Visualization of self-delivering hydrophobically modified siRNA cellular internalization
Ly, S., Navaroli, D. M., Didiot, M.-C., Cardia, J., Pandarinathan, L., Alterman, J. F., Fogarty, K., Standley, C., Lifshitz, L. M., Bellve, K. D., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1005 · Cited by 132
Crooke, S. T., Baker, B. F., Witztum, J. L., Kwoh, T. J., Pham, N. C., Salgado, N., McEvoy, B. W., Cheng, W., Hughes, S. G., Bhanot, S., et al. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0650 · Cited by 129 · cited 1×
“The level of toxicity will be related to the sequence of the ASO and careful selection of clinical candidates may mitigate risk (72).”
BackgroundChan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.36 · Cited by 128
Liver as a target for oligonucleotide therapeutics
Sehgal, A., Vaishnaw, A. K., & Fitzgerald, K. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.045 · Cited by 121
Cursiefen, C., Viaud, E., Bock, F., Geudelin, B., Ferry, A., Kadlecová, P., Lévy, M., Mahmood, S. A., Colin, S., Thorin, É., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.03.038 · Cited by 116
Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
Kim, R., Emi, M., Tanabe, K., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20696 · Cited by 114
Oligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress
Sharma, V. K., & Watts, J. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.144 · Cited by 112
Srinivasan, S. K., Tewary, H. K., & Iversen, P. L. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.131 · Cited by 109
Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism
Hu, J., Liu, J., & Corey, D. R. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.10.013 · Cited by 107
Self-citationSensible use of antisense: how to use oligonucleotides as research tools
Myers, K. J., & Dean, N. M. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01420-0 · Cited by 105
Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103 · cited 1×
“Clinical trials have revealed decreased ApoC-III levels, reducing cardiovascular risk and improving insulin sensitivity (141,142).”
BackgroundApproving a Problematic Muscular Dystrophy Drug
Kesselheim, A. S., & Avorn, J. (2016) · JAMA · doi:10.1001/jama.2016.16437 · Cited by 103
Corey, D. R. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0107-8 · Cited by 97
Self-citationOff‐Target Effects Related to the Phosphorothioate Modification of Nucleic Acids
Winkler, J., Stessl, M., Amartey, J., & Noe, C. R. (2010) · ChemMedChem · doi:10.1002/cmdc.201000156 · Cited by 96
Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing
Liu, J., Hu, J., & Corey, D. R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr780 · Cited by 93
Self-citationSchmidt, K., Prakash, T. P., Donner, A. J., Kinberger, G. A., Gaus, H. J., Low, A., Østergaard, M. E., Bell, M., Swayze, E. E., & Seth, P. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx060 · Cited by 93
Vickers, T. A., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv920 · Cited by 87
Targeting telomerase-expressing cancer cells
Ouellette, M. M., Wright, W. E., & Shay, J. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01279.x · Cited by 87
Nikan, M., Osborn, M. F., Coles, A. H., Godinho, B. M., Hall, L. M., Haraszti, R. A., Hassler, M. R., Echeverria, D., Aronin, N., & Khvorova, A. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.50 · Cited by 85
Telomeres and Telomerase: From Discovery to Clinical Trials
Corey, D. R. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.12.001 · Cited by 73
Self-citationKeeping the biotechnology of antisense in context
Stein, C. A. (1999) · Nature Biotechnology · doi:10.1038/6909 · Cited by 68
Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides
Wang, Z., Jeon, H. Y., Rigo, F., Bennett, C. F., & Krainer, A. R. (2012) · Open Biology · doi:10.1098/rsob.120133 · Cited by 65
Therapeutic approaches for spinal muscular atrophy (SMA)
Scoto, M., Finkel, R. S., Mercuri, E. M., & Muntoni, F. (2017) · Gene Therapy · doi:10.1038/gt.2017.45 · Cited by 61
Alnylam terminates revusiran program, stock plunges
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt1216-1213 · Cited by 53
Henry, S. P., Johnson, M., Zanardi, T. A., Fey, R. A., Auyeung, D. J., Lappin, P. B., & Levin, A. A. (2012) · Toxicology · doi:10.1016/j.tox.2012.06.005 · Cited by 50
Anderson, E. M., Miller, P. S., Ilsley, D. D., Marshall, W., Khvorova, A., Stein, C. A., & Benimetskaya, L. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700901 · Cited by 42
Proof of Mechanism of Antisense Drugs
Crooke, S. T. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.145 · Cited by 42
Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
Niemietz, C., Chandhok, G., & Schmidt, H. (2015) · Molecules · doi:10.3390/molecules201017944 · Cited by 37
Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets
Souza, E. B. D., Cload, S. T., Pendergrast, P. S., & Sah, D. W. Y. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.115 · Cited by 35
Regarding “Eteplirsen for the treatment of Duchenne muscular dystrophy”
Unger, E. F., & Califf, R. M. (2016) · Annals of Neurology · doi:10.1002/ana.24842 · Cited by 34
Chen, Z., Monia, B. P., & Corey, D. R. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025563v · Cited by 32
Self-citationRelative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells
Benimetskaya, L., Lai, J. C. H., Khvorova, A., Wu, S., Hua, E., Miller, P. S., Zhang, L.-M., & Stein, C. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1294 · Cited by 32
Donner, A. J., Yeh, S. T., Hung, G., Graham, M. J., Crooke, R. M., & Mullick, A. E. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.40 · Cited by 30
Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells
Miller, J. R. C., Pfister, E. L., Liu, W., André, R., Träger, U., Kennington, L. A., Lo, K., Dijkstra, S., Macdonald, D., Ostroff, G. R., et al. (2017) · Scientific Reports · doi:10.1038/srep46740 · Cited by 28
Tam, Y. K., Madden, T. D., & Hope, M. J. (2016) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1221955 · Cited by 20
The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy
van der Ploeg, A. T. (2017) · New England Journal of Medicine · doi:10.1056/nejme1712106 · Cited by 19
Evaluating the Mechanism of Action of Antiproliferative Antisense Drugs
Crooke, S. T. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.123 · Cited by 18
Won, J. I., Zhang, J., & McCullough, P. A. (2017) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0834 · Cited by 13
Adams, R. A., Nicke, B., Pohlenz, H., & Sohler, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137640 · Cited by 12
With Alnylam's amyloidosis success, RNAi approval hopes soar
Sheridan, C. (2017) · Nature Biotechnology · doi:10.1038/nbt1117-995 · Cited by 10
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Expanding the medicinal chemistry synthetic toolbox
Boström, J., Brown, D. G., Young, R. J., & Keserü, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.116 · Cited by 665
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Metadata
- Authors
- Shen, X., & Corey, D. R.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-12
- Volume
- 46
- Issue
- 4
- Pages
- 1584-1600
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2771932281
- Cited by
- 632
- References
- 135
- FWCI
- 23.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.